Interim Results From the MIRACEL Study Now Reported In the Renal Anaemia Disease Knowledge Centre at EPG Online

LONDON, (Marketwire - February 05, 2009) - EPG Health Media, specialists in e-communication solutions and digital publishing for the health sector, today announced that they have published the interim results of the MIRACEL study within the Renal Anaemia 'disease knowledge centre' at www.epgonline.org.

MIRACEL is the first real-life study to investigate switching the treatment of Chronic Kidney Disease (CKD) patients on dialysis from commonly used shorter-acting erythropoiesis-stimulating agents (ESAs) directly to the once monthly administration of the drug Mircera®, using pre-filled syringes.

Initial results confirm that Mircera® maintains haemoglobin (Hb) levels in CKD patients within a narrow range. Keeping Hb in a narrow target range has become a hot issue for health authorities in the last year with international guidelines recommending it be kept between 11-12 g/dL.(1)

"Health care professionals face a big challenge in treating CKD patients, with many patients experiencing Hb fluctuations outside of recommended range, putting them at a higher risk of death or hospitalisation. The results of the MIRACEL study highlight a great opportunity for physicians and nurses to provide better patient care, with an effective and simplified approach." said Chris Cooper, EPG Health Media. "By including the details of the study and its interim results within the Renal Anaemia disease knowledge centre, we aim to help European doctors stay current, and in turn, make more informed clinical decisions."

More information about this study and details of the data presented at the 41st Annual Meeting of the American Society of Nephrology (ASN) can be found within the MIRACEL study section of the Renal Anaemia disease knowledge centre. To access the material, healthcare professionals will be required to register (for free) or login with their EPG username and password.

The Renal Anaemia disease knowledge centre focuses on the treatment of Chronic Kidney Disease (CKD), a condition which is characterised by a gradual and permanent loss of kidney function that worsens as it progresses from stages 1 to 5. One of the most common complications of CKD is anaemia. Anaemia in patients with CKD causes debilitating weakness and fatigue, altered cognitive function, and a negative impact on quality of life and wellbeing. The Renal Anaemia disease knowledge centre is one of more than twenty interactive knowledge centres that form part of the EPG Online interactive knowledge 'library' developed for doctors and healthcare professionals. Other disease knowledge centres focus on a range of topics including asthma, non-small cell lung cancer, Parkinson's disease, hepatitis and chronic myeloid leukaemia (CML).

In addition to the disease specific Knowledge Centres, EPG Online contains more than 50,000 pages of drug and clinical information as well as safety alerts, drug reviews, guidelines, clinical study results, evidence based commentary and findings, medical news and journal abstracts. EPG was established in 2000, it is an independent website dedicated to providing Healthcare Professionals (HCPs) access to the most recent best practice diagnosis, clinical and patient management guidance.

About EPG Health Media.

EPG Health Media is part of UK based IMR International Ltd, a private limited Company specialising in the delivery of e-communication and digital information solutions. The Company's activities fall within three key areas of competency; electronic publishing; e-marketing/communications solutions and market research.

(1) Gilbertson D. T. et al. Hemoglobin Level Variability: Associations with Mortality. Clin J Am Soc Nephrol 3: 133-138, 2008 [http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=471722&ProfileId=&sourceType=1]

Contacts: EPG Health Media Charlotte Batten Public Relations (+44) 01892 667512 Email: press@epghealthmedia.com

Posted: February 2009

View comments

Hide
(web5)